Search

Your search keyword '"Chronic obstructive lung disease -- Care and treatment"' showing total 24 results
Start Over Descriptor "Chronic obstructive lung disease -- Care and treatment" Publisher normans media ltd.
24 results on '"Chronic obstructive lung disease -- Care and treatment"'

1. Forthcoming and Available Therapies for Allergy, Infectious Diseases and COVID-19

Subjects
Reslizumab -- Forecasts and trends, Marburg virus disease -- Care and treatment, Lassa fever -- Care and treatment, Benralizumab -- Forecasts and trends, Chronic obstructive lung disease -- Care and treatment, Atopic dermatitis -- Care and treatment, Communicable diseases -- Care and treatment, Medical research -- Forecasts and trends, Lopinavir -- Forecasts and trends, Omalizumab -- Forecasts and trends, COVID-19 -- Care and treatment, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-June 5, 2020-: Forthcoming and Available Therapies for Allergy, Infectious Diseases and COVID-19 (C)1994-2020 M2 COMMUNICATIONS RDATE:05062020 The 'Technology Breakthroughs Driving Allergy & Infectious Disease Therapy' report has been [...]

Published
2020

2. AstraZeneca's triple-combination therapy approved in China for patients with COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Medical supplies, Neurophysiology, Technology, Lung diseases, Business, Business, international, Bevespi Aerosphere (Medication)
Abstract

M2 PRESSWIRE-December 23, 2019-: AstraZeneca's triple-combination therapy approved in China for patients with COPD (C)1994-2019 M2 COMMUNICATIONS RDATE:23122019 - First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device in [...]

Published
2019

3. Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease

Subjects
Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Neurophysiology, Lung diseases, Respiratory tract diseases, Business, Business, international, Bevespi Aerosphere (Medication)
Abstract

M2 PRESSWIRE-June 19, 2019-: Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease (C)1994-2019 M2 COMMUNICATIONS RDATE:19062019 First approval of [...]

Published
2019

4. Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease

Subjects
Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Neurophysiology, Lung diseases, Formoterol, Respiratory tract diseases, Business, Business, international
Abstract

M2 PRESSWIRE-June 19, 2019-: Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease (C)1994-2019 M2 COMMUNICATIONS RDATE:19062019 First global approval and only triple-combination therapy in a [...]

Published
2019

5. CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Business, Business, international, Bevespi Aerosphere (Medication)
Abstract

M2 PRESSWIRE-October 19, 2018-: CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease (C)1994-2018 M2 COMMUNICATIONS RDATE:19102018 AstraZeneca today announced that the Committee [...]

Published
2018

6. AZ's Fasenra fails in Phase III COPD study

Subjects
AstraZeneca PLC -- Product development, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international, Fasenra (Medication)
Abstract

M2 PRESSWIRE-May 11, 2018-: AZ's Fasenra fails in Phase III COPD study (C)1994-2018 M2 COMMUNICATIONS RDATE:11052018 AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab failed to significantly reduce exacerbations in patients [...]

Published
2018

7. Chronic Obstructive Pulmonary Disease: 2018 Pipeline Highlights

Subjects
Chronic obstructive lung disease -- Care and treatment, Business, Business, international
Abstract

M2 PRESSWIRE-April 19, 2018-: Chronic Obstructive Pulmonary Disease: 2018 Pipeline Highlights (C)1994-2018 M2 COMMUNICATIONS RDATE:19042018 The 'Chronic Obstructive Pulmonary Disease Pipeline Highlights - 2018' report has been added to ResearchAndMarkets.com's [...]

Published
2018

8. CSA Medical gains FDA's breakthrough device designation and IDE approval for RejuvenAir System for treating COPD with C

Subjects
United States. Food and Drug Administration, Chronic obstructive lung disease -- Care and treatment, Clinical trials, Bronchitis, Lung diseases, Technology, Medical equipment, High technology industry, Medical research, Chemistry
Abstract

M2 PHARMA-April 4, 2019-CSA Medical gains FDA's breakthrough device designation and IDE approval for RejuvenAir System for treating COPD with CB (C)2019 M2 COMMUNICATIONS Cryotherapy technology company CSA Medical reported [...]

Published
2019

9. CSA Medical gains FDA's breakthrough device designation and IDE approval for RejuvenAir System for treating COPD with C

Subjects
United States. Food and Drug Administration, Chronic obstructive lung disease -- Care and treatment, Clinical trials, Bronchitis, Lung diseases, Technology, Medical equipment, High technology industry, Medical research, Business
Abstract

M2 EQUITYBITES-April 4, 2019-CSA Medical gains FDA's breakthrough device designation and IDE approval for RejuvenAir System for treating COPD with CB (C)2019 M2 COMMUNICATIONS http://www.m2.com Cryotherapy technology company CSA Medical [...]

Published
2019

10. Elsius Biomedical Inc. - Lifesaving Biomedical Tech Revolutionizes Circulatory

Subjects
Premature infants -- Care and treatment, Chronic obstructive lung disease -- Care and treatment, Business, Business, international
Abstract

M2 PRESSWIRE-May 17, 2017-: Elsius Biomedical Inc. - Lifesaving Biomedical Tech Revolutionizes Circulatory (C)1994-2017 M2 COMMUNICATIONS RDATE:16052017 Elsius Biomedical Inc. Lifesaving Biomedical Tech Revolutionizes Circulatory At Elsius Biomedical, our goal [...]

Published
2017

11. Chronic Obstructive Pulmonary Disease Pipeline Highlights 2017-2020

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical research, Business, Business, international
Abstract

M2 PRESSWIRE-February 15, 2017-: Chronic Obstructive Pulmonary Disease Pipeline Highlights 2017-2020 (C)1994-2017 M2 COMMUNICATIONS RDATE:15022017 Dublin - Research and Markets has announced the addition of the 'Chronic Obstructive Pulmonary Disease [...]

Published
2017

12. GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD | GSK

Subjects
GlaxoSmithKline PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Business, Business, international
Abstract

M2 PRESSWIRE-December 2, 2016-: GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD | GSK (C)1994-2016 M2 COMMUNICATIONS RDATE:02122016 London UK -- GlaxoSmithKline [...]

Published
2016

13. GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD | GSK

Subjects
GlaxoSmithKline PLC -- Planning, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Planning, Company business planning, Business, Business, international
Abstract

M2 PRESSWIRE-November 21, 2016-: GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD | GSK (C)1994-2016 M2 COMMUNICATIONS RDATE:21112016 GlaxoSmithKline plc (LSE/NYSE: [...]

Published
2016

14. Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD - GSK

Subjects
United States. Securities and Exchange Commission -- Planning, GlaxoSmithKline PLC -- Planning, Chronic obstructive lung disease -- Care and treatment, Corticosteroid drugs -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Business, international
Abstract

M2 PRESSWIRE-June 3, 2016-: Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD - GSK (C)1994-2016 M2 COMMUNICATIONS RDATE:03062016 London -- Acceleration of [...]

Published
2016

15. NICE rejects AstraZeneca's Daxas as a treatment for COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Chemistry
Abstract

M2 PHARMA-February 13, 2017-NICE rejects AstraZeneca's Daxas as a treatment for COPD (C)2017 M2 COMMUNICATIONS The National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca's Daxas (roflumilast) as [...]

Published
2017

16. NICE rejects AstraZeneca's Daxas as a treatment for COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Business
Abstract

M2 EQUITYBITES-February 13, 2017-NICE rejects AstraZeneca's Daxas as a treatment for COPD (C)2017 M2 COMMUNICATIONS http://www.m2.com The National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca's Daxas (roflumilast) [...]

Published
2017

17. NICE rejects AstraZeneca's Daxas as NHS treatment for certain patients with COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Enzyme inhibitors, Chemistry
Abstract

M2 PHARMA-February 10, 2017-NICE rejects AstraZeneca's Daxas as NHS treatment for certain patients with COPD (C)2017 M2 COMMUNICATIONS AstraZeneca's (LON: AZN) drug Daxas has been rejected by the National Institute [...]

Published
2017

18. NICE rejects AstraZeneca's Daxas as NHS treatment for certain patients with COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Enzyme inhibitors, Business
Abstract

M2 EQUITYBITES-February 10, 2017-NICE rejects AstraZeneca's Daxas as NHS treatment for certain patients with COPD (C)2017 M2 COMMUNICATIONS http://www.m2.com AstraZeneca's (LON: AZN) drug Daxas has been rejected by the National [...]

Published
2017

19. GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD | GSK

Subjects
GlaxoSmithKline PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Business, Business, international
Abstract

M2 PRESSWIRE-October 20, 2015-: GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD | GSK (C)1994-2015 M2 COMMUNICATIONS RDATE:20102015 London, UK -- GlaxoSmithKline [...]

Published
2015

20. GSK submits once-daily closed triple combination COPD therapy FF/UMEC/VI application in the EU

Subjects
Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Chemistry
Abstract

M2 PHARMA-December 5, 2016-GSK submits once-daily closed triple combination COPD therapy FF/UMEC/VI application in the EU (C)2016 M2 COMMUNICATIONS Bio-pharmaceuticals company Innoviva (NasdaqGS:INVA) stated on Friday that GlaxoSmithKline (LSE:GSK)(NYSE:GSK) has [...]

Published
2016

21. GSK submits once-daily closed triple combination COPD therapy FF/UMEC/VI application in the EU

Subjects
Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Business
Abstract

M2 EQUITYBITES-December 5, 2016-GSK submits once-daily closed triple combination COPD therapy FF/UMEC/VI application in the EU (C)2016 M2 COMMUNICATIONS http://www.m2.com Bio-pharmaceuticals company Innoviva (NasdaqGS:INVA) stated on Friday that GlaxoSmithKline (LSE:GSK)(NYSE:GSK) [...]

Published
2016

22. GSK announces regulatory filing once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

Subjects
GlaxoSmithKline PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Chemistry
Abstract

M2 PHARMA-November 22, 2016-GSK announces regulatory filing once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD (C)2016 M2 COMMUNICATIONS Pharmaceutical company GlaxoSmithKline plc (LSE:GSK)(NYSE:GSK) said on Monday that it [...]

Published
2016

23. GSK announces regulatory filing once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

Subjects
GlaxoSmithKline PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Business
Abstract

M2 EQUITYBITES-November 22, 2016-GSK announces regulatory filing once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD (C)2016 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company GlaxoSmithKline plc (LSE:GSK)(NYSE:GSK) said on Monday that [...]

Published
2016

24. GlaxoSmithKline and Innoviva announce Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD

Subjects
United States. Food and Drug Administration -- Planning, GlaxoSmithKline PLC -- Planning, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Planning, Company business planning, Business
Abstract

M2 EQUITYBITES-June 3, 2016-GlaxoSmithKline and Innoviva announce Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD (C)2016 M2 COMMUNICATIONS http://www.m2.com GlaxoSmithKline plc (LSE:GSK), [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results